Compare Ally Financial Inc (ALLY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ally Financial Inc vs BIO-TECHNE Corp — how do they compare? Ally Financial Inc trades at $45.64 (market cap $13.97B), while BIO-TECHNE Corp trades at $71.44 (market cap $11.11B). The key difference: Ally Financial Inc is the larger of the two by market cap, and Ally Financial Inc pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ALLY | TECH | |
|---|---|---|
Market Cap | $13.97B | $11.11B |
Sector | Financials | Health |
52-Week High | $47.25 | $71.38 |
52-Week Low | $35.96 | $43.31 |
Dividend Yield | 2.63% | 0.45% |
Enterprise Value | — | $11.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $45.59, up 1.06% today, with a bearish technical signal but strong analyst support. The stock shows attractive valuation with a P/E of 11.07 and P/B of 1.05, supported by consistent earnings beats in recent quarters. Recent news highlights value potential and a strategic focus on auto lending and digital banking, with a dividend payment scheduled for May 2026.
The outlook is positive given the consensus price target of $55.25, implying significant upside. Risks include declining operating cash flow and macroeconomic pressures on net interest margins. The stock presents a value opportunity with disciplined capital return, but investors should monitor credit quality and interest rate sensitivity.
Bio-Techne (TECH) trades at $71.30, up 0.21% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, while fundamentals reveal high valuation multiples (P/E 101.84) amid declining net margins (6.01% in 2025). Recent earnings were mixed with one beat and two misses in the last four quarters. Cash flow improved in 2026 projections, and the balance sheet remains solid with $152.86M cash.
The pending acquisition at $73.00 per share limits near-term upside but provides a floor. Risks include shareholder litigation questioning the deal's fairness and execution volatility. Analyst consensus is evenly split between Buy and Hold, with the price target slightly below current levels. The primary opportunity is the acquisition premium, while fundamental weakness in profitability poses a risk if the deal falters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
